Ra Medical Systems, Inc., Receives SFDA Clearance to Market EX-308 in China

June 19, 2006 - Carlsbad, CA
Ra Medical Systems, Inc., a privately held developer, manufacturer and seller of laser/light-based devices for medical applications, announced today the company received approval from China's medical device regulating authority (SFDA) to sell the PHAROS EX-308 Laser System in China.

China represents approximately 20% of the world's total population, and psoriasis is one of the most common skin disorders. China 's dermatologists and psoriasis and vitiligo patients will benefit greatly with the addition of Ra Medical’s PHAROS Laser Phototherapy System.

Melissa Burstein, Ra Medical’s Vice President, noted, "Ra Medical continues to make the most advanced technologies available to growing markets.” Ra Medical’s PHAROS EX-308 Excimer laser system is becoming increasingly more popular in the US and around the world. “Our entrance into China with the EX-308 signifies a major milestone in this effort."

Ra Medical’s EX-308 Laser provides physicians a powerful tool in the fight against psoriasis and vitiligo. Since its introduction, the EX-308 Laser therapy has demonstrated its ability to reduce and directly addresses patient compliance concerns versus other forms of therapy that require ongoing and repeated treatment.

# # #

This media release may contain forward-looking statements that constitute Ra Medical Systems' current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, and our ability to expand regulatory approvals. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of products, unanticipated increases in expenses, market developments that vary from the current expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. For additional information on factors that could affect Ra Medicals performance, please call the company directly. Ra Medical Systems expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Ra Medical systems' expectations or any change in events, conditions or circumstances on which any such statement is based. but not limited to, clinical studies and results of those studies, management, market potential, distributor success, market size, international approvals, FDA clearances, marketing, future events and performance of the company, which involve risks and uncertainties that could materially affect actual results.